No Data
Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
Neurocrine (NBIX) Gets a Buy From J.P. Morgan
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
Neurocrine Biosciences: Balancing Strategic Priorities With Regulatory Challenges – Analyst Maintains Hold Rating
Neurocrine Biosciences Unveils KINECT-HD Data Demonstrating Consistent Efficacy Of INGREZZA In Huntington's Disease Chorea Across 19 Subgroups, Showing Positive Impact On Emotional Health
Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $184 From $181
No Data
No Data